Swedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease specialist at $467 million as the craze for biotech I
California’s Applied Molecular Transport has become the latest biotech to go for an IPO during the pandemic, aiming to raise $100 million to take an oral ulcerative colitis drug into phase
